Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cannamedical hybrid cannabis extract THC25:CBD25
- Development stage
- Phase 3
- Lead developer
- Cannamedical Pharma
- Modality
- Small Molecules
- Administration
- Sublingual
01
Overview
Cannamedical hybrid cannabis extract THC25:CBD25 is a full-spectrum medicinal cannabis extract developed by Cannamedical Pharma GmbH. It features a balanced 1:1 ratio of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), each at a concentration of 25 mg/mL. The extract is produced via ethanol extraction from hybrid cannabis strains and formulated in a medium-chain triglyceride (MCT) oil carrier for sublingual administration. It targets the endocannabinoid system, specifically the CB1 and CB2 receptors, to provide analgesic effects. The product is available by prescription in Germany for the treatment of chronic pain and is currently being evaluated in the 'Pain Ease' observational study (DRKS00026906).
- Brand names
- Cannamedical hybrid cannabis extract THC25:CBD25
- Other names
- Cannamedical Hybrid Cannabis Extract THC25:CBD25
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)CNR2 (Cannabinoid receptor type 2)ENT1 (Solute carrier family 29 member 1)GPR55 (G protein-coupled receptor 55)PPARG (Peroxisome proliferator-activated receptor gamma)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on Cannamedical hybrid cannabis extract THC25:CBD25.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cannamedical hybrid cannabis extract THC25:CBD25.